Biomaterial Database

Problems in evaluating the effect of secretolytic agents on the mucociliary system by means of radioactive particles. 1977

W Aurnhammer, and N Konietzko, and H Matthys

In a double-blind cross-over study the effect of two secretolytic agents on the mucociliary clearance was tested in 8 patients with mild chronic obstructive bronchitis. Clearance was assessed from the removal rate of previously inhaled sulfur colloid particles, tagged with 99Tcm. For the interpreatation of the results, obtained by this method, it is essential to take into account the pattern of particle deposition. For example there was a faster clearance under placebo compared to the secretolytic drugs because of a more central deposition. To overcome this problem different approaches were therefore tested. The following constellations proved to be useful in assessing the effect of secretolytic drugs: (1) change in deposition patter; (2) clearance rate, if no change in deposition takes place; (3) clearance rate from a peripheral area of the lung. An attempt to apply a simple three compartment model proved to be unpracticable probably becuase of the complexity of the mechanism involved. One of these mechanisms could be a reversal in mucus transport, observed at least in one patient, a finding which might be of pathophysiological relevance.

UI	MeSH Term	Description	Entries
D008176	Lung Volume Measurements	Measurement of the amount of air that the lungs may contain at various points in the respiratory cycle.	Lung Capacities,Lung Volumes,Capacity, Lung,Lung Capacity,Lung Volume,Lung Volume Measurement,Measurement, Lung Volume,Volume, Lung
D009093	Mucus	The viscous secretion of mucous membranes. It contains mucin, white blood cells, water, inorganic salts, and exfoliated cells.
D001964	Bromhexine	A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p744)	Aparsonin,Bisolvon,Bromhexin,Bromhexin BC,Bromhexin Berlin-Chemie,Bromhexin-ratiopharm,Bromhexine Hydrochloride,Bromhexine Monohydrochloride,Brotussol,Darolan,Dur-Elix,Famel Bromhexine,Flegamin,Flubron,Hustentabs-ratiopharm,Mucohexine,NA-274,Quentan,Tesacof,bromhexin von ct,BC, Bromhexin,Bromhexin Berlin Chemie,Bromhexin BerlinChemie,Bromhexin ratiopharm,Bromhexine, Famel,Bromhexinratiopharm,Dur Elix,DurElix,Hustentabs ratiopharm,Hustentabsratiopharm,Hydrochloride, Bromhexine,Monohydrochloride, Bromhexine,NA 274,NA274,ct, bromhexin von,von ct, bromhexin
D001980	Bronchi	The larger air passages of the lungs arising from the terminal bifurcation of the TRACHEA. They include the largest two primary bronchi which branch out into secondary bronchi, and tertiary bronchi which extend into BRONCHIOLES and PULMONARY ALVEOLI.	Primary Bronchi,Primary Bronchus,Secondary Bronchi,Secondary Bronchus,Tertiary Bronchi,Tertiary Bronchus,Bronchi, Primary,Bronchi, Secondary,Bronchi, Tertiary,Bronchus,Bronchus, Primary,Bronchus, Secondary,Bronchus, Tertiary
D001991	Bronchitis	Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI.	Bronchitides
D002908	Chronic Disease	Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D002986	Clinical Trials as Topic	Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.	Clinical Trial as Topic
D004311	Double-Blind Method	A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.	Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004341	Drug Evaluation	Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.	Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005990	Glycerol	A trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism. It is used as a solvent, emollient, pharmaceutical agent, or sweetening agent.	1,2,3-Propanetriol,Glycerin,1,2,3-Trihydroxypropane,Glycerine